Skip to main content

Table 3 Cox proportional hazards model with CTC BL

From: Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients

 

PFS

OS

 

Hazard ratio

95% CI

P

Hazard ratio

95% CI

P

Baseline CTC status (CTC BL )

 < 5 CTC (CTCBL-)

1.00

  

1.00

  

 ≥ 5 CTC (CTCBL+)

1.55

1.19–2.01

0.001

2.79

2.04–5.63

< 0.001

Age at inclusion

 Per year

0.99

0.98–1.00

0.207

1.00

0.99–1.01

0.938

Number of metastatic sites

 One site

1.00

  

1.00

  

 Multiple sites

0.97

0.66–1.43

0.892

0.71

0.41–1.23

0.227

Site of metastasis

 Bone

1.00

  

1.00

  

 Visceral/local

0.98

0.67–1.46

0.939

1.75

1.00–3.01

0.052

 Both

1.07

0.71–1.63

0.739

2.55

1.41–4.60

0.002

Line of therapy

 1

1.00

  

1.00

  

 2

1.35

0.93–1.95

0.113

1.45

0.92–2.28

0.112

 ≥ 3

1.91

1.40–2.59

< 0.001

2.01

1.37–2.96

< 0.001

Molecular Subtypes

 HR+/HER2-

1.00

°

 

1.00

  

 HER2+

1.10

0.79–1.52

0.577

1.09

0.72–1.63

0.695

 TNBC

1.92

1.36–2.71

< 0.001

2.86

1.91–4.27

< 0.001

  1. Bold P values indicate statistical significance.
  2. HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.